Busardò F P, Kyriakou C, Napoletano S, Marinelli E, Zaami S
Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Rome, Italy.
Eur Rev Med Pharmacol Sci. 2015 Dec;19(23):4654-63.
Gamma-hydroxybutyrate (GHB) is a short chain fatty acid endogenously produced within the central nervous system (CNS) and acts as a precursor and metabolite of the inhibitory neurotransmitter γ-aminobutyric acid (GABA). Although, it is an illegal recreational drug of abuse, its sodium salt (sodium oxybate) has been utilized as a medication for a number of medical conditions. The first aim of this review was to focus on current applications of sodium oxybate for the treatment of narcolepsy, with a particular emphasis on the key symptoms of this disorder: cataplexy and excessive daytime sleepiness (EDS). Secondly, the effectiveness of sodium oxybate therapy for the treatment of alcohol withdrawal syndrome (AWS) and the maintenance of alcohol abstinence has been assessed. Nowadays, sodium oxybate is the first-line treatment for narcolepsy and it is highly effective in meliorating sleep architecture, decreasing EDS and the frequency of cataplexy attacks in narcoleptic patients. Sodium oxybate currently finds also application in the treatment of AWS and the maintenance of alcohol abstinence in alcoholics. Most of the studies evaluating the efficacy of GHB in the treatment of AWS use a dosage of 50 mg/kg divided in three or four administrations per day. Human studies showed that GHB (dose of 50 mg/kg, divided in three administrations per day) is capable to increase the number of abstinent days, reduce alcohol craving and decrease the number of drinks per day. However, there is limited randomized evidence and, thus, GHB cannot be reliably compared to clomethiazole or benzodiazepines. Some randomized data suggest that GHB is better than naltrexone and disulfiram regarding abstinence maintenance and prevention of craving in the medium term i.e. 3-12 months. It is recommended that GHB should be used only under strict medical supervision, since concerns about the abuse/misuse of the drug and the addiction potential have been arisen.
γ-羟基丁酸(GHB)是一种在中枢神经系统(CNS)内源性产生的短链脂肪酸,是抑制性神经递质γ-氨基丁酸(GABA)的前体和代谢产物。尽管它是一种非法的消遣性滥用药物,但其钠盐(羟丁酸钠)已被用作多种医疗状况的药物。本综述的首要目的是关注羟丁酸钠在发作性睡病治疗中的当前应用,特别强调该疾病的关键症状:猝倒和日间过度嗜睡(EDS)。其次,评估了羟丁酸钠治疗酒精戒断综合征(AWS)及维持戒酒的有效性。如今,羟丁酸钠是发作性睡病的一线治疗药物,在改善发作性睡病患者的睡眠结构、减少EDS和猝倒发作频率方面非常有效。羟丁酸钠目前也用于治疗AWS及维持酗酒者戒酒。大多数评估GHB治疗AWS疗效的研究使用的剂量为50mg/kg,每天分三次或四次给药。人体研究表明,GHB(剂量为50mg/kg,每天分三次给药)能够增加戒酒天数、减少对酒精的渴望并减少每日饮酒量。然而,随机对照证据有限,因此,GHB无法与氯美噻唑或苯二氮䓬可靠地进行比较。一些随机数据表明,在中期(即3 - 12个月)维持戒酒和预防渴望方面,GHB比纳曲酮和双硫仑更好。建议仅在严格的医疗监督下使用GHB,因为已经出现了对该药物滥用/误用及成瘾潜力的担忧。